Five ALK inhibitors including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib have been approved to date for the treatment of ALK-positive lung cancer in the European Union and the United States [7,8,9,10,11,12]. This evidence concerns the gene ALK and lung cancer.